Monte Carlo simulations for Sellas Life Sciences' REGAL study
To make an informed decision to invest in a research stage biotech company one has to face the task to assess the likelihood that the therapy will ultimately achieve regulatory approval. Using SELLAS Life Sciences` REGAL study as an example we illustrate how Monte Carlo simulations can provide insights into the probability of success of a clinical trial.